Recent Pfizer Press Releases

  • 9/5/18 8:50 am EDT

    Phase II data accepted for late-breaker news session at 2018 EADV Congress

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced its investigational oral Janus kinase 3 (JAK3) inhibitor PF-06651600 received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body.1,2 The Breakthrough Therapy designation for alopecia areata was supported bymore...
  • 9/4/18 8:38 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of six tranches of notes: $300,000,000 aggregate principal amount of floating rate notes due 2023 $1,000,000,000 aggregate principal amount of 3.000% notes due 2021 $1,000,000,000 aggregate principal amount of 3.200% notes due 2023 $1,000,000,000 aggregate principal amount of 3.600% notes due 2028 $700,000,000 aggregatemore...
  • 8/30/18 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension study (B5161004). The Phase 2 study (B5161002), did not meet its primary efficacy endpoint, which was to demonstrate a difference in the mean change from baseline in 4more...
  • 8/27/18 5:21 am EDT

    ATTR-ACT Showed that Tafamidis Significantly Reduced the Combination of All-cause Mortality and Cardiovascular-related Hospitalizations

    Data Showed a 30% Reduction in the Risk of Mortality and 32% Reduction in the Rate of Cardiovascular-related Hospitalizations with Tafamidis in People with Transthyretin Amyloid Cardiomyopathy versus Placebo

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the primary results from the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study, which showed tafamidis significantly reduced the hierarchical combination of both all-cause mortality and frequency of cardiovascular-related hospitalizations compared to placebo over a 30-month period (P=0.0006) in patients with wild-type or variant (hereditary) transthyretin amyloidmore...
  • 8/22/18 5:00 pm EDT

    Amendments accelerate anticipated primary completion dates for both ARCHES and EMBARK trials

    NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI® (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC). These amendments accelerate timelines for the anticipated primary completionmore...
  • 8/1/18 1:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 10 mg twice-daily (BID) for at least eight weeks, followed by XELJANZ 5 mg BID or 10 mg BID, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.1 XELJANZ is the firstmore...
  • 7/31/18 6:45 am EDT
    • Second-Quarter 2018 Revenues of $13.5 Billion, Reflecting 2% Operational Growth
    • Second-Quarter 2018 Reported Diluted EPS(1) of $0.65, Adjusted Diluted EPS(2) of $0.81
    • Raised 2018 Financial Guidance for Adjusted Diluted EPS(2) by $0.05 to a Range of $2.95 to $3.05
    • Lowered Midpoint of 2018 Revenue Guidance Range by $500 Million Solely to Reflect Recent Unfavorable Changes in Foreign Exchange Rates
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2018 and raised 2018 financial guidance for Adjusted diluted EPS(2). Results for the second quarter and first six months of 2018 and 2017(3) are summarized below. OVERALL RESULTSmore...
  • 7/31/18 6:00 am EDT

    The European Commission decision marks the approval of Pfizer’s first therapeutic oncology biosimilar

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has approved TRAZIMERA™,1 a biosimilar to Herceptin®* (trastuzumab), for the treatment of human epidermal growth factor (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.2 This approval follows the recommendation from the Committee for Medicinal Products for Human Use in May 2018.1 “more...
  • 7/24/18 1:30 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer today announced it will increase its commitment to U.S. manufacturing with a $465 million investment to build one of the most technically advanced sterile injectable pharmaceutical production facilities in the world in Portage, Michigan. This U.S. investment will strengthen Pfizer’s capability to produce and supply critical, life-saving injectable medicines for patients around the world. Known as Modular Aseptic Processing (MAPmore...
  • 7/20/18 4:24 pm EDT

    NIVESTYM™, a biosimilar to Neupogen ® (filgrastim), is Pfizer’s fourth biosimilar to be approved by the FDA

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NIVESTYM™ (filgrastim-aafi), a biosimilar to Neupogen1 (filgrastim), for all eligible indications of the reference product. “The FDA approval of NIVESTYM marks an important step in helping expand access to critical treatment options for patients with neutropenia, many of whom have cancer and can be hospitalized formore...